START Shanghai was visited by a high-level delegation of the J&J’s pharmaceutical division-Jassen Pharma.
This high-level delegation was formed by seven high officials (VPs and senior directors) of the Jassen Pharmaceutical. This delegation was lead by Dr. Chris Takimoto (Translational Medicine and Early Development), and the team has been shown around both START Shanghai’s office and the FUSCC-START phase I clinical trial center. During the meeting with START Shanghai and FUSCC’s officials, Dr. Chris Takimoto gave a detailed presentation on Jassen Pharmaceutical’s development. Both START Shanghai and members of the delegation agree to keep contact for potential future cooperation
This delegation consists of the following members:
Jim Backer, Worldwide VP, Global Strategic Marketing, Oncology
Kristen Hollingsworth, Vice President, Office of External Innovation
Chris Takimoto, Vice President, Translational Medicine and Early Development
Nicole Chieffo, Senior Director, Global Clinical Operations
Dave Yazujian, Vice President, Strategy and Operations
Sandy Rattray, Vice President, Regulatory Affairs
Michael Meyers, Vice President and Compound Development Team Leader – Zytiga
Photo: the head of nurse, Ms. Gu was giving an introduction of the FUSCC-START phase I clinical trial center to the visitors.